News

02 Jul 2021

Essity’s acquisition of ABIGO Medical is completed

The process following the acquisition of the remaining 25% of the shares of ABIGO Medical AB is completed and the company is now a wholly owned subsidiary of Essity. As per the terms of the transaction, ABIGO Medicals pharma business has been divested and sold to the company’s founder Jan G. Smith.

ABIGO Medical is a Swedish medical solutions company with its head office in Gothenburg, Sweden. The company has about 170 employees. Essity acquired 75% of ABIGO Medical in February 2020. ABIGO Medical develops, manufactures and markets products including the Sorbact® technology, which is a clinically established innovation for advanced wound care. In the first quarter of 2021, Essity’s organic net sales in wound care increased 2.1%.

Source: essity.com

27 Apr 2021

Essity acquires remaining shares in ABIGO Medical AB

Hygiene and health company Essity has signed an agreement today to acquire the remaining 25% of the shares in the Swedish medical solutions company ABIGO Medical AB. Essity acquired 75% of ABIGO Medical in February 2020. Following the acquisition, ABIGO Medical will be a wholly owned subsidiary of Essity in the product category Medical Solutions. The shares are being acquired from founder and chairman of the board Jan G. Smith at a valuation of SEK 900m for 100% of the company on a debt-free basis.

“We are very pleased with this acquisition, which is a natural step in our ambition to strengthen our positions in medical solutions. ABIGO has unique expertise and innovation capacity that will contribute to accelerating Essity’s growth in advanced wound care,” says Magnus Groth, President and CEO, Essity.

ABIGO Medical AB is a Swedish medical solutions company with its head office in Gothenburg, Sweden, and was founded in 1989 by the brothers Jan G. and Leif Smith. The company has about 170 employees. ABIGO Medical AB develops, manufactures and markets products including the Sorbact® technology, which is a clinically established innovation for advanced wound care. In the first quarter of 2021, Essity’s organic net sales in wound care increased 2.1%.

In parallel with the acquisition, a process is under way to streamline ABIGO Medical’s operations. The parties have concluded an agreement in principle under which Jan G. Smith will, in the near future, acquire the pharma business comprising products such as ear and eye care as well as vitamins.

“I have had a close relationship with Essity for many years and I am very confident that this is the right step in ABIGO’s journey of growth,” says Jan G. Smith.

Essity’s acquisition will be finalized in May 2021.

Source: essity.com

Download press release

01 Apr 2020

ABIGO Medical Group and Covid-19

In the current circumstances with the spread of Covid-19 around the world, which necessitate the implementation of various measures and initiatives to protect our fellow humans and companies around the globe, the team at ABIGO Medical Group would like to reassure you that we are doing everything we can to minimize the impact.

 

We are working according to three fundamental principles:

  • Protecting our fellow human beings. ABIGO Medical’s top priority is to secure the health and welfare of our employees, customers, suppliers, distributors and partners, as well as their families. Naturally, we are following the recommendations issued by the Public Health Agency in this regard.
  • The company’s social responsibility. It is extremely important to us at ABIGO Medical that both as a company and as individual employees we do out utmost to limit the spread of this virus and to protect at-risk groups in the population. This cannot be emphasised enough.
  • Maintain our commitments to our customers and partners. Our commitments to you are very important to us. Our planning is focused on continuity and endurance throughout our supply chains. At present, we do not see any major issues with, or threats to, ensuring delivery in the short-term, but as everyone knows this may change quickly depending on the development of events. We ask for your understanding and continued cooperation should greater challenges arise.

At the same time, we are looking ahead. We face a challenging period, but we are well-equipped and we are confident that we will emerge stronger than ever from this time.

You can rest assured that at ABIGO Medical we are doing our utmost to minimise the effects of this crisis.

 

You are most welcome to contact us if you have any questions.

 

Kind regards,

Jan G Smith
CEO

Artur Aira
Executive Vice President

27 Feb 2020

Essity acquires 75% of the medical solutions company ABIGO Medical AB

Hygiene and health company Essity has signed an agreement to acquire 75% of the Swedish medical solutions company ABIGO Medical AB. The company as a whole is valued at SEK 900m on a debt-free basis. ABIGO Medical AB develops, manufactures and markets products including the Sorbact® technology, which is a clinically established innovation for advanced wound care. Jan G. Smith will retain a 25% stake in the company and remain as chairman of the board.

 

ABIGO Medical AB is a Swedish company with its head office in Gothenburg, Sweden, and was founded in 1989 by the brothers Jan G and Leif Smith. The company has about 170 employees and reported net sales of approximately SEK 403m in 2019. ABIGO Medical AB is currently a key partner and sub-supplier to Essity.

“The acquisition is a good strategic fit for Essity and strengthens the innovation capacity of our Medical Solutions business. ABIGO Medical has leading innovations in advanced wound care that reduce the spread of bacteria without increasing resistance to antibiotics,” says Magnus Groth, President and CEO of Essity.

“Essity’s values and strategy are well aligned with ABIGO’s ambitions for the future and with Essity as a partner, we believe there is great potential to continue our shared journey of growth,” says Jan G. Smith.

Sorbact® is a technology that Essity, through ABIGO Medical AB, already uses in its wound care products to prevent and treat infections. It does this using a natural mode of action that binds bacteria and fungi. Sorbact® does not contain antiseptics or other toxic substances, which is positive for both the patient and the environment.

The completion of the transaction is subject to customary regulatory approvals and closing is expected to take place during the second quarter of 2020.

 

Source: Essity.com

14 Aug 2019

Pharmaboardroom, Healthcare & Life Sciences Review 2019 – an interview with ABIGO Medical founder and CEO Jan G. Smith

Article published by Pharmaboardroom for their Healthcare & Life Sciences Review 2019 – an interview with ABIGO Medical founder and CEO Jan G. Smith on the company success to date and plans onwards.

Founded in 1989 by brothers Jan G and Leif Smith, ABIGO Medical is a successful private Swedish pharmaceutical and medical technology company with a focus on bacterial and infection control in the fight against antibiotic resistance. Jan G Smith, chairman and CEO, explains his unique approach to business, the steps for successful internationalization for SMEs and the advantages of manufacturing in Sweden.“

Read the full article here.

 

 

 

 

 

 

 

21 May 2018

Swedish success solution against external otitis changes ownership

ABIGO Medical AB acquires Uppsala-based Amellnova AB, which will become part of the Abigo group. Otinova, used for treatment of inflammation of the ear canal (external otitis) has been Amellnova’s bestseller and will strengthen Abigo’s position within the therapeutic area of Ear, Nose & Throat (ENT), by offering prescription free drugs within the entire range of self-care products for the ear/ear canal.

Through its products Vaxol, Otovent and Otinova, Abigo becomes a strong partner for the health care and pharmacy industry within the therapeutic area for ENT. Abigo strengthens its position within health care and self-care, focusing on fighting antibiotic resistance as well as providing top of the line products, which prevents and treats infections effectively.

Each year, over 100 000 people in Sweden are affected with external otitis (inflammation of the ear canal). Until now, the treatment has mostly consisted of prescription type drugs containing steroids and antibiotics, something Abigo will substantially improve on by offering Otinova, free of both steroids and antibiotics. Otinova prevents and treats effectively and is prescription free to great benefit for the healthcare industry and individuals affected by external otitis.

– Otinova is a valuable addition to Abigo, a very interesting product and market success, which also carries a lot of potential for the future. Abigo is a full service pharmaceutical and medical technology company. We have the competency and resources to develop a broader product portfolio and thus increase our sales substantially, a most exciting opportunity.  We will consolidate the interest for Otinova in Scandinavia and then in the rest of the Nordic region and further on globally. We are already marketing our products successfully in over 65 countries says Jan G. Smith, CEO, Abigo.

– Abigo have the power to market Otinova in many more markets than Amellnova had. Its full potential will now be reached optimally. In addition, Otinova complement other Abigo products excellently. Abigo now has three products within this product area in its portfolio and that will give Otinova the prerequisites to become the great product success it deserves, says Claes Lundberg, founder of Amellnova.

19 Dec 2016

Unique investment by Swedish pharmaceutical company

ABIGO Medical is the only company manufacturing advanced wound care products in Sweden. The company has substantial international presence with strong growth. Products are sold to 70 countries, with turnover of approximately 300 MSEK. Now ABIGO gears up further. By investing 30 MSEK in their production facility, they expect an annual production increase by 15-20 %.

ABIGO Medical’s strictly organic growth strategy and their self-financed R&D-operation has resulted in a great international success, with an ever increasing demand. In order to meet this, ABIGO has invested heavily in the expansion of the production facility in Askersund. While many pharmaceutical companies nowadays choose to move production abroad, ABIGO sees the advantages of maintaining both headquarters, R&D and production in Sweden.

“In recent years, we’ve seen a steady growth and the trend seems to continue. At the end of 2016, we expect to be approximately 60 employees”, says Fredrik Stenbäcker, Plant Manager at ABIGO’s production facility in Askersund, recently expanded to a total of 5000 sqm.

Swedish innovation in the fight against antibiotic resistance

In 1989, the brothers and entrepreneurs Jan G. Smith and Leif Smith founded ABIGO Medical AB, with a focus on delivering innovative methods of infection control and to reduce the use of antibiotics. The infection preventive dressing Sorbact® eventually became the flagship of the business and is also the main reason behind the new investment.

“Sorbact® offers fantastic opportunities, particularly in view of the global challenges of infections and antimicrobial resistance”, Jan G. Smith, CEO at ABIGO Medical explains.

Sorbact® prevents and treats infections by binding bacteria to the surface of the dressing, without releasing any chemical agents into the wound. The bacteria are removed when the dressing is changed. By preventing infections, Sorbact® also helps to reduce the need of antibiotics, hence lessening the risk of spreading multi-resistant bacteria. The Sorbact® method is an innovation, based on Swedish research. In a recently published international and controlled clinical study1, Sorbact® was compared to a standard dressing among women undergoing cesarean section. The result confirmed the efficacy and cost-effectiveness of Sorbact®. Excellent results in international studies combined with many years of clinical experience, has led to a sharp increase in the use of the Sorbact® For example, all French University Hospitals use Sorbact®.

Financially independent

ABIGO Medical is an entrepreneurial company with financial stamina and long-term perspective as core values. The company has also reinvested its profits in the business over the years.

“To be financially independent and not having to rely on venture capital is one of our incentives,” says Leif Smith, President at ABIGO Group.

Leif owns and actively manages the company together with his brother Jan.

“We do not like the quarterly economy hysteria. It’s neither good for business nor for Sweden.”“We have seen many good products and innovations succumbing to the venture capital’s lack of patience”, Jan adds.

According to the brothers, the fight against multi-resistant bacteria is the most exciting area and this is where ABIGO has a unique competence. The prevention of infections in itself is an incredibly large area and there are a multitude of applications for the innovations owned by ABIGO.

“We have barely scratched the surface,” Leif Smith says.

For more information,
contact Björn Larsson, bjorn.larsson@abigo.se, phone: +46 766 201 725

1. Stanirowski PJ et al. Surgical Infections 2016; [ahead of print]. DOI: 10.1089/sur.2015.223. The full study is available here: https://online.liebertpub.com/doi/pdfplus/10.1089/sur.2015.223

Click her for:

Images

About Sorbact®

About ABIGO Medical

 

28 Jun 2016

ABIGO Medical expands the Sorbact® range of infection preventive dressings with the Foam Gentle Border dressing

The new Sorbact® Foam Gentle Border dressing further extends the use of Sorbact® Technology with an all-in-one dressing with gentle silicone adhesive border, especially suitable for patients with sensitive or vulnerable skin. The Sorbact® range of microbial binding dressings help preventing infections as well as managing already infected and hard-to-heal wounds. Infected wounds mean longer healing times, leading to unnecessary suffering for the patient and increased costs for the community.

Sorbact® Foam Gentle Border is an atraumatic all-in-one dressing that reduces bioburden in a wide range of wounds. It consists of a green Sorbact® wound contact layer, polyurethane foam, soft silicone adhesive borders and a vapor permeable polyurethane backing film. Sorbact® Foam Gentle Border is intended for use in management of clean, colonized, contaminated or infected wounds with moderate exudate levels, such as surgical wounds, traumatic wounds, pressure ulcers, diabetic ulcers and foot and leg ulcers.

The skin-friendly soft silicone adhesive borders make Sorbact® Foam Gentle Border dressing especially suitable in patients with sensitive or vulnerable skin, i.e. elderly patients, patients who are sensitive to common plasters or surgical tape, patients with thin skin due to long-term use of systemic corticosteroids, and children who are experiencing pain when removing a patch.

Sorbact® Foam Gentle Border is based on the Sorbact® Technology with a wound contact surface more attractive for microorganisms than the wound bed. The microorganisms bind irreversibly to Sorbact®, and are removed at dressing change. Sorbact® Foam Gentle Border can be used prophylactically to prevent infections in different types of wounds and is available in three different sizes.

– Adding the Foam Gentle Border dressing to the Sorbact® product range is a response to customer and patient needs, says Mattias Andrup, Medical Affairs Director at ABIGO Medical. We are delighted to be able to offer this gentle all-in-one dressing combined with the Sorbact® Technology advantage.

Sorbact® Foam Gentle Border was launched in conjunction with the 26th conference of European Wound Management Association, EWMA 2016, 11–13 May in Bremen, Germany.

Contact Björn Larsson, Marketing Communication Director, bjorn.larsson@abigo.se, +46 31 36 14 887

More about Sorbact®
Common wound microorganisms bind to Sorbact®, such as Staphylococcus aureus, Streptococcus species, Escherichia coli, Pseudomonas aeruginosa and Candida albicans, and including MRSA¹ bacteria. No mechanisms of resistance to Sorbact® have been described. Sorbact® does not contain or release toxic agents and can be used with children and during pregnancy. Sorbact® is available in a comprehensive range of dressing types and sizes and, through our partners and distributors, used in in more than 65 countries. For more information on Sorbact® please visit https://www.abigo.com/products/wound-fungus/sorbact/

About ABIGO Medical
ABIGO Medical is a Swedish entrepreneurial pharmaceutical company that owns, develops, manufactures and markets pharmaceuticals and medical devices. ABIGO Medical has a wide range of non-prescription and prescription drugs, as well as a range of medical products in advanced wound management and ear, nose and throat (ENT) treatment, as well as food for special medical purposes. The company was founded in 1989 by the current owners, brothers Jan G. Smith and Leif Smith, both still actively involved in the ABIGO management. ABIGO’s products are sold and used in over 65 countries, through its own sales organizations and partners. Consolidated turnover for 2015/2016 will be approximately SEK 275 million and continued growth is expected, which is reinvested in research and development. To meet the surge in demand, including Sorbact®, more than 40 million SEK is invested to multi-double capacity at the company’s production plant in Askersund.

Sorbact® is a registered trademark of ABIGO Medical AB.

References:
Rönner AC, Curtin J, Karami N, and Rönner U. Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressings. J Wound Care 2014; 23(10):484, 486-488.

09 Mar 2016

NEW STUDY – shows that Sorbact® Surgical dressing is a cost-effective way to prevent surgical site infection

Surgical site infections (SSI) are common after cesarean section, and can lead to higher morbidity rates, prolonged hospitalization, and an increased number of hospital readmissions.1

A recently published study among 543 women undergoing elective or emergency low transverse cesarean section showed that the risk of SSI was significantly reduced with Sorbact® Surgical Dressing compared to a standard surgical dressing.2

This randomized controlled trial confirmed the efficacy and cost-effectiveness of Sorbact® Surgical Dressing in SSI prevention among women undergoing cesarean section.

Read full study ›

 

References: 1. Jenks PJ, Laurent M, et al. Clinical and economic burden of surgical site infection (SSI) and predicted financial consequences of elimination of SSI from an English hospital. J Hosp Infect 2014; 86:24-33. 2. Stanirowski PJ, Bizon M, et al. Randomized Controlled Trial Evaluating Dialkylcarbamoyl Chloride (DACC) Impregnated Dressings for the Prevention of Surgical Site Infections in Adult Women Undergoing Cesarean Section. Hosp Infect Epid 2016; [in press]

10 Feb 2016

ABIGO Medical expands the Sorbact® product range with the novel Superabsorbent wound dressing

Infected wounds mean longer healing times, leading to unnecessary suffering for the patient and increased costs for the community. Sorbact® range of microbial binding dressings help preventing infections as well as managing already infected and hard-to-heal wounds. The new Sorbact® Superabsorbent dressing extends the use of Sorbact® to include high to excessive exuding wounds.

Sorbact® dressings prevent and treat wound infections by lowering the bioburden naturally, thereby improving clinical outcome and reducing patients suffering and healthcare costs. Using Sorbact® Technology, a modified wound contact surface more attractive for microorganisms to bind to than the wound bed, Sorbact® is irreversibly binding microorganisms, and removing them at dressing change.

The new Sorbact® Superabsorbent is the latest addition to the product range and the only microbial binding superabsorbent dressing available. It is intended for use in the management of wounds with high to excessive exudate levels, such as surgical wounds, traumatic wounds, pressure ulcers, diabetic ulcers and foot and leg ulcers. It combines the Sorbact® Technology with a superabsorbent core and a water repellent backing to prevent exudate strike through, available in the following sizes: 10x10cm, 10x20cm, 20x20cm and 20x30cm.

“Adding the Superabsorbent dressing is a response to customer and patient needs,” says Mattias Andrup, Medical Affairs Director at ABIGO Medical. “Customer reactions so far, have been very positive. It’s everything customers need from a superabsorbent dressing – and now with the Sorbact® Technology advantage.

Sorbact® Superabsorbent is launched initially in Europe, followed by other regions.

More about Sorbact®
Sorbact® binds to common wound microorganisms, such as Staphylococcus aureus, Streptococcus species, Escherichia coli, Pseudomonas aeruginosa and Candida albicans, and including MRSA¹ bacteria. No mechanisms of resistance to Sorbact® have been described.
Sorbact® is environmentally friendly, does not contain or release toxic agents, is non-allergenic, and can be used with children and during pregnancy.
Sorbact is available in a comprehensive range of dressing types and sizes and, through our partners and distributors, used in in more than 65 countries.

For more information on Sorbact® please visit www.abigo.com/products/wound-fungus/sorbact/

About ABIGO Medical
ABIGO Medical is a Swedish entrepreneurial pharmaceutical company that owns, develops, manufactures and markets pharmaceuticals and medical devices. ABIGO Medical has a wide range of non-prescription and prescription drugs, as well as a range of medical products in advanced wound management and ear, nose and throat (ENT) and in food for special medical purposes. The company was founded in 1989 by the current owners, brothers Jan G. Smith and Leif Smith, both still actively involved in the ABIGO management. ABIGO’s products are sold and used in over 60 countries, through its own sales organizations and partners. ABIGO’s turnover exceeds 200 million SEK annually with solid, continuous growth profitability, which is reinvested in research and development.

More information is available at www.abigo.com

Contact: Anders Elliot – Global Director Medical Device Division, anders.elliot@abigo.se, +46 31 748 49 50
Sorbact is a registered trademark of ABIGO Medical AB.

¹ Rönner U & A.C. et al. Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressings. J Wound Care,
vol 23, no 10, Oct. 2014.